Alfasigma acquires the European license for bentracimab from PhaseBio
— The agreement covers the countries of the European Union, the European Economic Area, the United Kingdom, Ukraine, Russia and the CIS — Bentracimab is a human monoclonal antibody fragment to counteract the antiplatelet effects of ticagrelor — After the recent acquisition of Lumeblue®, Alfasigma’s pipeline is enriched with a biotechnological drug Alfasigma has entered into […]